UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by a Party other than the Registrant $\ \square$

Filed by the Registrant $\ oxdots$

Che	ck the	appropriate box:	
	Preliminary Proxy Statement		
	Confidential, For Use of the Commission Only (as permitted by 14a-6(e)(2))		
	Definitive Proxy Statement		
\boxtimes	Definitive Additional Materials		
	Solid	Soliciting Material Pursuant To §240.14a-12	
		ARROWHEAD PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter)	
		(Name of Person(s) Filing Proxy Statement if other than the Registrant)	
Payı	ment o	of filing fee (Check the appropriate box):	
\boxtimes	No f	No fee required.	
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1)	Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
	Fee paid previously with preliminary materials.		
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the dafiling.		
	(1)	Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing party:	
	(4)	Date filed:	

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on March 14, 2019.

ARROWHEAD PHARMACEUTICALS, INC.

Meeting Information

Meeting Type: Annual Meeting For holders as of: January 23, 2019

Date: March 14, 2019 **Time:** 10:00 AM PT **Location:** Meeting live via the Internet-please visit

www.virtual shareholder meeting.com/ARWR 2019.

The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit www.virtualshareholdermeeting.com/ARWR2019 and be sure to have the information that is printed in the box marked by the arrow

→XXXX XXXX XXXX (located on the following page).

ARROWHEAD PHARMACEUTICALS, INC. 225 SOUTH LAKE AVENUE, SUITE 1050 PASADENA, CA 91101

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT FORM 10-K

How to View Online:

Have the information that is printed in the box marked by the arrow isit: www.proxyvote.com. (located on the following page) and

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) *BY INTERNET*: www.proxyvote.com 2) *BY TELEPHONE*: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow **If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before February 28, 2019 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote By Internet:

Before The Meeting:

Go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.

During The Meeting:

Go to www.virtualshareholdermeeting.com/ARWR2019. Have the information that is printed in the box marked by the arrow \(\sigma \times \times

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

5210-916097

Voting Items

The Board of Directors recommends you vote FOR ALL the following director nominees:

1. Election of Directors

Nominees

01) Christopher Anzalone 04) Michael S. Perry
02) Mauro Ferrari 05) William Waddill
03) Douglass Given

The Board of Directors recommends you vote FOR proposals 2 and 4 and "1 year" on proposal 3:

- 2. To approve, in an advisory (non-binding) vote, the compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.
- 3. To recommend, in an advisory (non-binding) vote, the frequency of an advisory vote to approve the compensation paid to the Company's named executive officers.
- 4. To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2019.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.